Study design and patients
SARS‐Cov‐2 infection
DEL
This study was approved by the independent ethics committee of the Hospital Nuestra Señora del Prado, Spain (Clinical study approval number 22/21) and registered at Trial registration website This double‐blind, pilot randomized clinical trial of buccopharyngeal mucosa administered high polyphenolic olive oil versus no therapy was conducted from July 1, 2021 to August 31, 2022, coordinated by the Pediatric Department of the Hospital Universitario Nuestra Señora del Prado. Participants were selected from the epidemiological database of nearly 7900 contacts of recent COVID‐19‐diagnosed people with a positive result from a SARS‐CoV‐2 reverse transcriptase–polymerase chain reaction or antigen test performed at the Laboratory of the public Hospital Nuestra Señora del Prado belonging to the National Health system at the city of Talavera de la Reina, Spain.Adult men and nonpregnant or breast‐feeding women were eligible if they had been recent contacts of people diagnosed of COVID‐19 and had no symptoms nor had a positive result for SARS‐Cov‐2 infection. Patients were excluded if they were symptomatic, if they had had COVID‐19 in the previous 6 months or if they had participated in another clinical trial related to COVID‐19. More details of the trial can be found in the protocol (Supporting Information 